Using stem cell-derived exosomes to reduce muscle problems caused by cancer treatment
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes
This study is looking at how tiny particles from embryonic stem cells might help reduce muscle problems caused by the cancer drug doxorubicin, which can lead to inflammation and weakness in patients, with the hope of finding a new way to support muscle health for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-10758185 on NIH RePORTER |
What this research studies
This research investigates how exosomes derived from embryonic stem cells can help alleviate muscle dysfunction caused by the chemotherapy drug doxorubicin. Doxorubicin is effective for treating cancer but can lead to inflammation and muscle weakness in patients. The study aims to understand the mechanisms behind this muscle toxicity and explore how these exosomes can reduce inflammation and improve muscle health. By examining the effects of these exosomes on muscle cells and inflammatory responses, the research seeks to find a potential therapeutic approach for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing treatment with doxorubicin who are experiencing muscle dysfunction and fatigue.
Not a fit: Patients who are not receiving doxorubicin or those without muscle dysfunction related to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help cancer patients maintain muscle strength and reduce fatigue during chemotherapy.
How similar studies have performed: Other research has shown promise in using stem cell-derived therapies for reducing inflammation and improving muscle function, suggesting a potential for success in this approach.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Singla, Dinender Kumar — University of Central Florida
- Study coordinator: Singla, Dinender Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.